Sign in

Hugh Kyle

Research Analyst at Private Investor

Hugh Kyle is an analyst at Private Investor, specializing in investment research and portfolio analysis, although public records do not indicate coverage of specific companies or provide detailed performance metrics. His career background, exact role seniority, specific companies covered, track record, and professional credentials are not available from reputable business directories, LinkedIn results, or major industry publications. There is no information confirming registration with FINRA, securities licenses, or notable industry achievements. Due to the absence of verifiable public data, a comprehensive and specific professional profile for Hugh Kyle cannot be provided at this time.

Hugh Kyle's questions to IGXT leadership

Question · Q3 2023

Asked a wide range of questions covering the RIZAFILM commercial rollout with Gensco, potential expansion of the Exeltis partnership, the pediatric RIZAFILM timeline, market appeal for new Tilray products, the status of a CDMO contract, potential for other technologies, and updates on VetaFilm, the 'power product', tadalafil, the atai pipeline, and potential for new analyst research coverage.

Answer

RIZAFILM will launch in Q1 2024 via Gensco to customers like CVS. Partnership expansions are being considered but depend on initial success. Pediatric RIZAFILM is a 2025 item. The company is 'cautiously optimistic' about the new Tilray products. The CDMO agreement should be finalized in Q1 2024. The focus is on film products. A VetaFilm partnership is expected by year-end. Tadalafil is back on track. Partnering for Montelukast depends on Q2 data. No new analyst coverage is confirmed.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts